申请人:Gaucher Berangere
公开号:US20120040957A1
公开(公告)日:2012-02-16
Compounds of formula (I) wherein X1, X3; X4 and X6, each independently of the others, represents a nitrogen atom or CR2, with the proviso that at least one of X1, X3; X4 and X6 represents a nitrogen atom; X2 represents C—H, C—(C1-C6alkyl), C—(C1-C6alkoxy), C-halogen, C—COOH; X5 represents C—H or C—(C1-C6alkyl), C-halogen; R1 and R2, independently of one another, represent hydrogen or a substituent selected from hydroxy, halogen, carboxy, amino, C1-C6alkylamino, di(C1-C6alkyl)amino, mercapto, cyano, nitro, C1-C6alkyl, C1-C6alkoxy, C1-C6alkylthio, C1-C6alkylamino-carbonyloxy, C2-C6alkenyl, C2-C6alkynyl, C1-C6alkylcarbonyloxy, C1-C6alkyl-sulfonyloxy, C1-C6heteroalkylcarbonyloxy, C5-C6heterocyclyl-carbonyloxy, C1-C6heteroalkyl, C1-C6heteroalkoxy, wherein heteroalkyl, heteroalkoxy groups or heterocyclyl comprise 1, 2 or 3 heteroatoms selected from nitrogen, oxygen and sulphur, in which substituents the alkyl moieties are unsubstituted or further substituted by halogeno, cyano, hydroxy, C1-C4alkoxy, C1-C4alkylcarbonyl, C1-C4alkoxycarbonyl, unsubstituted or substituted phenoxy or phenylcarbonyl, unsubstituted or substituted C5-C6heterocyclyl or carboxy; A1 represents a divalent group of one of the formulae —O—(CH
2
)
m
—(CH
2
)—, —S—(CH
2
)
m
—(CH
2
)— or —(C═O)O—(CH
2
)
m
—(CH
2
)—, wherein the (CH
2
)
m
moiety is optionally substituted by C1-C4alkyl, C2-C4alkenyl, C3-C6cycloalkyl, C3-C6cycloalkylmethyl, morpholinomethyl, halogen, carboxy, hydroxy, C1-C4alkoxy; C1-C4alkoxyC1-C4alkyl, C1-C4alkoxy(C1-C4alkylenoxy)C1-C4alkyl, benzyloxyC1-C4alkyl, amino, mono- or di-(C1-C4alkyl)amino or acylamino, in which substituents the alkyl moieties can be further substituted by
1
or more fluoro atoms m is
0, 1
or
2,
provided that the nunber of atoms in the direct chain between the two terminal valencies of A
1
is at least
3,
which group A
1
is linked to A
2
via the terminal (CH
2
)-moiety; A
2
is a group selected from C
3
-C
8
cycloalkylene; saturated and unsaturated
4
to
8
-membered heterocyclodiyl with
1, 2 or 3
heteroatoms selected from nitrogen, oxygen and sulphur, which group A
2
is unsubstituted or substituted; R
4
represents hydrogen or C
1
-C
4
alkyl; A
3
represents C
1
-C
4
alkylene, C
2
-C
4
alkenylene, >C═O, —C(O)C
1
-C
3
alkylene-, —C(═O)NH—, or a group selected from —C
2
H
4
NH—, —C
2H
4
O—, and —C
2
H
4
S— being linked to the adjacent NR
4
-group via the carbon atom; and G represents aryl or heteroaryl, which is unsubstituted or substituted and n is
0, 1
or
2;
or a pharmaceutically acceptable salts, hydrates or solvates thereof are valuable antibacterial agents.
化合物式(I)中,其中X1、X3、X4和X6分别独立地表示氮原子或CR2,但至少其中一个表示氮原子;X2表示C-H、C-(C1-C6烷基)、C-(C1-C6烷氧基)、C-卤素、C-COOH;X5表示C-H或C-(C1-C6烷基)、C-卤素;R1和R2独立地表示氢或从羟基、卤素、羧基、氨基、C1-C6烷基氨基、二(C1-C6烷基)氨基、巯基、氰基、硝基、C1-C6烷基、C1-C6烷氧基、C1-C6烷基硫基、C1-C6烷基氨基羰氧基、C2-C6烯基、C2-C6炔基、C1-C6烷基羰氧基、C1-C6烷基磺酰氧基、C1-C6杂烷基羰氧基、C5-C6杂环基羰氧基、C1-C6杂烷基、C1-C6杂烷氧基中选择的取代基,其中杂烷基、杂烷氧基或杂环基包括1、2或3个从氮、氧和硫选择的杂原子,在这些取代基中,烷基基团未取代或进一步取代为卤代、氰基、羟基、C1-C4烷氧基、C1-C4烷基羧基、C1-C4烷氧羰基、未取代或取代的苯氧基或苯基羧基、未取代或取代的C5-C6杂环基或羧基;A1表示一个二价基团,其中之一为式之一的基团-O-(CH2)m-(CH2)-、-S-(CH2)m-(CH2)-或-(C═O)O-(CH2)m-(CH2)-,其中(CH2)m基团可以选择地被C1-C4烷基、C2-C4烯基、C3-C6环烷基、C3-C6环烷基甲基、吗啉基甲基、卤素、羧基、羟基、C1-C4烷氧基取代;C1-C4烷氧基C1-C4烷基、C1-C4烷氧基(C1-C4烷氧基)C1-C4烷基、苄氧基C1-C4烷基、氨基、单取代或双取代(C1-C4烷基)氨基或酰基氨基,在这些取代基中,烷基基团可以进一步取代1个或多个氟原子,m为0、1或2,前提是A1的两个端面价之间的直链原子数至少为3,该基团A1通过端面(CH2)基团与A2相连;A2是选择自C3-C8环烷基、饱和和不饱和的1、2或3个从氮、氧和硫选择的杂环二基,该基团A2未取代或取代;R4表示氢或C1-C4烷基;A3表示C1-C4烷基、C2-C4烯基、>C═O、-C(O)C1-C3烷基、-C(═O)NH-或选择自-C2H4NH-、-C2H4O-和-C2H4S-的基团,通过碳原子与相邻的NR4基团相连;G表示未取代或取代的芳基或杂芳基,其中n为0、1或2;或其药学上可接受的盐、水合物或溶剂。这些化合物是有价值的抗菌剂。